Multiple endocrine neoplasia type 1 (MEN1) is an
|
|
- Theodora Chapman
- 5 years ago
- Views:
Transcription
1 JCEM ONLINE Advances in Genetics Endocrine Care Higher Risk of Aggressive Pancreatic Neuroendocrine Tumors in MEN1 Patients With MEN1 Mutations Affecting the CHES1 Interacting MENIN Domain Detlef K. Bartsch, Emily P. Slater, Max Albers, Richard Knoop, Brunhilde Chaloupka, Caroline L. Lopez, Volker Fendrich, Peter H. Kann, and Jens Waldmann Departments of Visceral, Thoracic, and Vascular Surgery (D.K.B., E.P.S., M.A., R.K., B.C., C.L.L., V.F., J.W.) and Gastroenterology (P.H.K.), Division of Endocrinology and Diabetology, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany Context: Sixty to 80% of multiple endocrine neoplasia type 1 (MEN1) patients develop pancreatic neuroendocrine neoplasias (s), which reveal an aggressive behavior in 10%-20% of patients. Causative MEN1 mutations in the interacting domains of the encoded Menin protein directly alter its regulation abilities and may influence the phenotype. Objective: The objective of the study was the evaluation of an association between MEN1 mutations in different interacting domains of Menin and the phenotype of s. Design: This was a retrospective analysis of a prospectively collected cohort of 71 genetically confirmed MEN1 patients at a tertiary referral center. Main Outcome Measures: Analysis of patients characteristics and clinical phenotype of s regarding the mutation type and its location in Menin interacting domains was measured. Results: Sixty-seven patients (93%) developed s after a median follow-up of 134 months. Patients with mutations leading to loss of interaction (LOI) with the checkpoint kinase 1 (CHES1) interacting domain codons ( ) compared with patients with mutations resulting in LOI with other domains (eg, JunD, Smad3) had significantly higher rates of functioning s (70% vs 34%), malignant s (59% vs 16%), and aggressive s (37% vs 9%), respectively. Patients with CHES1-LOI also had an increased -related mortality (20% vs 4.5%). Neither gender, age, nor the ABO blood types were associated with the phenotype of s. Conclusions: MEN1 patients with MEN1 mutations leading to CHES1-LOI have a higher risk of malignant s with an aggressive course of disease and disease-related death. (J Clin Endocrinol Metab 99: E2387 E2391, 2014) Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited disorder classically characterized by the development of neuroendocrine neoplasms in the endocrine pancreas (s), the pituitary, and parathyroid glands (1, 2). The syndrome is caused by germline mutations in the MEN1 gene, mapped to the 11q13 (3). More than 1300 different mutations without a ISSN Print X ISSN Online Printed in U.S.A. Copyright 2014 by the Endocrine Society Received December 16, Accepted July 15, First Published Online September 11, 2014 mutation hotspot have been reported (4). The MEN1 gene encodes for the Menin protein, which has been demonstrated to interact with a number of proteins that are involved in transcriptional regulation [JunD, phosphorylated mothers against decapentaplegic 3 (Smad3), nuclear factor- B (NF- B), checkpoint kinase 1 (CHES1)], genome stability (RPA2, FANCD2), cell division (NMHCII-A), Abbreviations: CHES1, checkpoint suppressor 1; CT, computed tomography; EUS, endoscopic ultrasonography; HDAC1, histone deacetylase 1; LOI, loss of interaction; MEN1, multiple endocrine neoplasia type 1; NF- B, nuclear factor- B;, neuroendocrine neoplasms in the endocrine pancreas; Smad3, phosphorylated mothers against decapentaplegic 3. doi: /jc J Clin Endocrinol Metab, November 2014, 99(11):E2387 E2391 jcem.endojournals.org E2387
2 E2388 Bartsch et al MEN1 Mutations in CHES1 Domain and Aggressive sj Clin Endocrinol Metab, November 2014, 99(11):E2387 E2391 and proliferation (NM23H1, apoptosis signal-regulating kinase) (4 7), respectively. PNENs represent the second most common manifestation of MEN1 with a prevalence up to 85% by the age of 50 years (1, 2, 8, 9). These s are nonfunctional or functional and carry low or high malignant potential. It has been shown that s together with thymic tumors represent the major cause of death in MEN1(8) and that 23% of patients with MEN1-s have an aggressive tumor growth with hepatic metastases leading to early death (10). At present there are neither clinical nor genetic parameters that reliably predict an aggressive or less aggressive phenotype of MEN1-s (11, 12). Therefore, no general consensus has been reached regarding the optimal timing and extent of surgery in MEN1-s (13, 14). However, a recent large scale analysis of the French Groupe d Etude des Tumeurs Endocrines group postulated that MEN1 patients with mutations affecting the JunD interacting domain had a higher risk of death secondary to a MEN1-associated neoplasia (15). The present study aimed to evaluate associations between the phenotype of s and the mutation type and its location in interacting domains to identify factors that predict an aggressive course of MEN1-s. Materials and Methods All MEN1 patients treated at the Department of Surgery, University Hospital Marburg, were documented in a prospective database since Patient demographics, clinical phenotypes, pathological findings, and follow-up were analyzed with special regard to s and other malignant NETs. In addition, laboratory data were reviewed to document the blood type. The study included only patients older than 18 years with a confirmed MEN1 gene germline mutation. The presence of MEN1 associated tumors was assessed by an annual routine screening program, which included the measurement of plasma hormone levels (insulin, proinsulin, gastrin, pancreatic polypeptide, vasoactive intestinal peptide, glucagon, chromogranin A) and imaging with endoscopic ultrasonography (EUS), abdominal magnetic resonance imaging, computed tomography (CT) of the thorax, somatostatin receptor scintigraphy, or Ga 68 -DOTATOC-positron emission tomography-ct, respectively (9, 16). All MEN1 patients with either biochemical evidence of functioning s or nonfunctioning s larger than 1 cm in size on imaging were recommended to undergo duodenopancreatic surgery. The diagnosis of s was established by plasma hormone levels (see above), imaging, especially EUS, and/or conventional histological and immunohistochemical examinations (chromogranin A, synaptophysin, insulin, gastrin) of resection specimens. All resected specimens were classified according to the World Health Organization criteria (17). Malignancy was determined on the strict criteria of lymph node or distant metastases. Aggressive disease was defined as the presence or development of distant metastases. The follow-up was based on the most recent screening examination until July All patients with s had annual follow-up screening examinations of the pancreas, including EUS or magnetic resonance imaging and somatostatin receptor scintigraphy or Ga 68 -DOTATOC-positron emission tomography-ct in case of Zollinger-Ellison syndrome as described previously (9, 16). The type of mutation was analyzed by comparing truncating mutations (nonsense, frame shift) vs nontruncating mutations (missense, in-frame deletions, or insertions) with special regard to the phenotype of s and also other malignant NENs. In addition, mutations affecting an interacting domain causing loss of interaction (LOI) with functional partners of Menin JunD (codons 1 40, , and ), NF- B (codons ), Smad3 (codons and ), Pem (codons ), NM23H1 (codons 1 486), RPA2 (codons 1 40 and ), FANCD2 (codons ), msin3a (codons ), histone deacetylase 1 (HDAC1; ), and CHES1 (codons ) according to the published mapping (4) were evaluated. The analysis of the locations of mutations included all types of mutations. For further analyses, the causes of death were categorized as secondary to a, secondary to a cancer of the MEN1 spectrum (eg, pancreas, thymus, bronchi, adrenal glands, parathyroid glands and pituitary gland), and death of a MEN1- unrelated cause. Statistics Time-to-event techniques were used to identify genotypephenotype correlations. Events of interest included occurrence of s, prevalence of functioning s, prevalence of malignant s, prevalence of aggressive s with distant metastases, prevalence of other malignant NETs, and cause of death of, respectively. The prognostic role of the phenotypic profiles for each phenotypic criterion was assessed using a Fisher s exact test. Odds ratios and contingency intervals were calculated for significant variables to quantify the relative risk. A value of P.05 was considered statistically significant. The intrafamilial heterogeneity could not be assessed because of the small sample size. Based on their blood types, patients were stratified into 2 groups: individual blood types (A, AB, B, or O), and 0 blood type vs non-0 blood type. To test for a general association between blood type and disease state, a Fisher s exact contingency table analysis was performed using 4 2 tables. Results Clinical characteristics and pathology Sixty-seven of 71 (93%) MEN1 patients (38 male, 33 female) of 56 families had s. The median age of diagnosis was 37 years (range 9 69 y). Fifty-eight of these patients (87%) underwent duodenopancreatic surgery, and the diagnosis of was confirmed by histopathology. The s were nonfunctional in 24 patients (41%) and functional in 34 patients (59%), including Zollinger-Ellison syndrome (n 20), insulinoma (n
3 doi: /jc jcem.endojournals.org E ), and vipoma (n 1). Of the 58 patients who underwent duodenopancreatic surgery, 44 patients (76%) had G1 tumors, 10 patients (17%) had G2 (Ki67 2% 10%) tumors, and for four patients grading was not available. Twenty-three patients (34%) had histologically verified malignant s (18 functioning, five nonfunctionings), which showed an aggressive course of disease with the development of distant metastases in 10 patients (15%). In addition, 8 of 71 patients (11%) had other malignant NETs, including thymic carcinoid (n 4) and bronchial NET (n 2) as well as gastric NET and adrenocortical cancer in one patient each, respectively (Supplemental Table 1). The patient with the gastric NET was very uncommon because it was a neuroendocrine carcinoma G3 (Ki67, 60%) with liver metastases, which developed during 2 years based on multiple small G1 gastric neuroendocrine neoplasias. After a median follow-up of 134 months (6 to 468 mo), 62 patients were alive, seven patients (9%) died due to MEN1-related cancers, and two patients died of MEN1- unrelated causes (one car accident, one pneumonia). The seven cancer deaths were caused by metastatic s in four patients, by metastatic thymic carcinoids in two patients, and by adrenocortical cancer in one patient, respectively. Gender and phenotype Male patients had a higher prevalence of s (100%) than females patients (88%, P.042). However, no significant gender difference was observed regarding the other phenotypic parameters (Supplemental Table 1). Blood type and phenotype The individual blood type was neither associated with the phenotype of s nor the risk of MEN1-related death. The same held true when comparing blood 0 vs non-blood 0 types (Supplemental Table 1). Genotype-phenotype comparisons A MEN1 gene mutation analysis identified the 45 different causative MEN1 gene mutations in the 71 patients of 56 families distributed throughout the gene. Identified mutations encompassed 36 truncating (10 nonsense, 26 frame shift mutations) and nine nontruncating mutations (eight missense, one in frame deletion). There was no statistically significant association between the genotype criteria truncating or nontruncating mutation and the phenotypic criteria of s or other malignant NETs (data not shown). Most mutations affected the interacting domains of JunD, Smad3, CHES1, and HDAC1, leading to LOI with these functional domains (Figure 1). Patients with CHES1-LOI had significantly higher rates of func- Figure 1. Location of MEN1 mutations and domains that interact with other proteins.
4 E2390 Bartsch et al MEN1 Mutations in CHES1 Domain and Aggressive sj Clin Endocrinol Metab, November 2014, 99(11):E2387 E2391 Table 1. Genotype/Phenotype Analysis of s in Genetically Confirmed MEN1 Patients LOI n Age Dx Functioning <30 y at Age >50 y Aggressive a Disease Overall Disease >50 y Aggressive Disease a DOD All (9 69) 34/71 (47%) 22/71 (31%) 23/71 (32%) 23/47 (49%) 10/71 (14.%) 27/71 (38%) 27/49 (55%) 12/71 (16.9%) 7/71 (9.9%) JunD (15 68) 12/31 (39%) 9/31 (29%) 7/31 (22.5%) 7/18 (39%) 1/31 (3.%) 8/31 (26%) 8/18 (44%) 2/31 (6.4%) 2/31 (6.4%) None JunD (9 69) 22/40 (55%) 13/40 (32.5%) 16/40 (40%) 16/32 (47%) 9/40 (22.5%) 19/40 (47.5%) 19/30 (63%) 10/40 (25%) 5/ %) Smad (9 69) 26/49 (52%) 15/49 (31%) 15/49 (31%) 15/31 (40.5%) 8/49 (16%) 19/49 (39%) 19/36 (53%) 10/49 (20%) 6/49 (12.5%) None Smad (12 50) 8/21 (38%) 7/22 (32%) 8/22 (36%) 8/14 (57.5%) 2/22 (9%) 8/22 (36%) 8/13 (61.5%) 2/22 (9%) 1/22 (4.5%) CHES (9 58) 19/27 (70%) 9/27 (33%) 16/27 (59%) 16/20 (80%) 8/27 (30%) 17/27 (63%) 17/21 (81%) 10/27 (37%) 5/25 (20%) None CHES (12 69) 15/44 (34%) 13/44 (29%) 7/44 (16%) 7/27 (26%) 2/44 (4.5%) 10/44 (23%) 10/28 (36%) 4/44 (9%) 2/44 (4.5%) HDAC (15 68) 15/29 (52%) 8/29 (27.5%) 9/29 (31%) 9/20 (45%) 3/29 (10%) 11/29 (38%) 9/19 (47%) 5/29 (17%) 2/29 (6.8%) None HDAC (9 69) 19/42 (45%) 14/42 (33%) 15/42 (36%) 15/28 (53%) 7/42 (16.5%) 1/42 (40%) 17/30 (56%) 9/42 (215%) 5/42 (12%) Abbreviations: DOD, dead of disease; Dx, diagnosis. a As determined by the development of distant metastases. tioning s (70% vs 34%), malignant s overall (59% vs 16%), and, by the age older than 50 years (80% vs 24%), aggressive s (30% vs 4.5%) and tended to a higher rate of -related death (15% vs 2.2%) than patients with LOI with other domains (Table 1). However, there was no difference regarding the grading of s between groups. Patients with CHES1-LOI also had higher rates of malignant disease overall (63% vs 23%) and aggressive course of malignant disease (37% vs 9%), leading to a tendency of a higher rate of disease-related death (20% vs 4.5%, P.089) and decreased survival (287 vs 422 months, P.01, Supplemental Figure 1). The presence of CHES1-LOI predicted a malignant, aggressive with a sensitivity and specificity of 76% and 71% (odds ratio and confidence intervals; also see Supplemental Table 2). In contrast, none of the eight other tested interacting domains, especially JunD, showed significant associations regarding the phenotype of s and other NETs (Table 1). Discussion It has been shown that truncating as well as nontruncating mutations can affect the interaction with known functional partners of Menin such as JunD, Smad3, and CHES1 (4 7). A recent French large-scale study of 806 patients reported a significantly higher risk of MEN1-related tumor death in patients with mutations affecting the JunD interacting domain (15). Using the same approach, the present study focused on a potential genotype-phenotype correlation with regard to the detailed clinicopathological characteristics of s in a well-defined, prospectively collected cohort of genetically confirmed MEN1 patients who were all treated under the same surgical philosophy. This analysis reveals for the first time that patients with mutations affecting the CHES1-interacting domain as compared with patients with mutations affecting the other domains (eg, JunD, Smad3) had significantly higher rates of functioning s, malignant s, aggressive s with the development of distant metastasis, and -related deaths, respectively. This is somehow in line with the French study (15) that also revealed a significant correlation (P.04) between CHES1-LOI and the phenotype when using the frailty model of Cox-hazard ratio. However, this correlation lost significance after the false discovery rate correction. In contrast to this study (15), a higher rate of MEN1- related tumor death in patients with JunD-LOI could not be demonstrated. The reasons for this controversial result remain speculative. It might be influenced by the heterogeneity across families, which could not be statistically determined in the present study and differing qualities of analyzed clinical data, respectively. In addition, the aggressive surgical attitude in our cohort might have changed the natural course of some aggressive s resulting in some bias. In accordance with previous studies, no mutational hot spot was evident, and there was no statistically significant association between the genotypic criteria truncating or nontruncating mutation (5, 14, 15). The presented cohort confirms the results of other studies (2, 8, 15) with regard to gender distribution; age of disease onset; rate of MEN1-related deaths; and the prevalence of primary hyperparathyroidism, pituitary tumors, adrenal neoplasms, thymic and bronchial NETs, respectively. This also holds true for the observation that thymic tumors occurred exclusively in male patients and the risk of MEN1-related death tended to be higher in male than in female patients (8, 15, 18, 19). In contrast to a previous study (20) of 105 MEN1 subjects, the presented study cannot confirm that MEN1 patients with the 0 blood type have a higher rate of GEP-NETs and NETs of the lung nor a significantly higher rate of metastatic tumors (Table 1). This controversial result might be partially caused by the high rate of s ( 90%) in both blood 0 type and nonblood 0 type in our cohort.
5 doi: /jc jcem.endojournals.org E2391 On the molecular mechanisms behind our observation can only be speculated. Menin is also required for the expression of cyclin dependent kinases such as p18 and p27 that maintain cells in a quiescent state. Menin can bind specific DNA directly and is involved in DNA repair through the CHES1 and other pathways (ATR-checkpoint kinase 1, FANCD2). At the molecular level, loss of function of CHES1 may lead to additional mutations by impairing DNA-repair mechanism that potentially accelerate cell division. Through these mechanisms, LOI with CHES1 may promote a more aggressive phenotype. Although the underlying mechanisms were not analyzed and remain unclear, identification of at-risk MEN1 mutations, such as those with CHES1-LOI, might be relevant for the indication for surgery in MEN1-s because this is a highly controversial issue. If CHES1-LOI would reliably indicate a high risk of a malignant and aggressive course of MEN1-s, it might be an important additional parameter for the decision for surgery. This hypothesis warrants confirmation in larger studies with the functional measurement of CHES1 activity in patients with mutations in codon positions The present study has some limitations as well as some strengths. It is limited by its relatively small sample size, the inability to calculate the heterogeneity across families, and the lack of molecular data on expression and function. In addition, the aggressive surgical attitude might have changed the natural course of some aggressive s, resulting in some bias. The strength of the study is the well-defined, prospectively collected patient cohort with detailed pathological and clinical follow-up data. Acknowledgments We are grateful to all the patients who participated in our screening program. Address all correspondence and requests for reprints to: Jens Waldmann, MD, Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, Marburg, Germany. jwaldmann@med.uni-marburg.de. Disclosure Summary: The authors have nothing to declare. References 1. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16: Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q J Med. 1996;89: Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science. 1997;276: Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29: Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat. 2002;20: Chandrasekharappa SC, Teh BT. Clinical and molecular aspects of multiple endocrine neoplasia type 1. Front Horm Res. 2001; 28: Busygina V, Kottemann MC, Scott KL, Plon SE, Bale AE. Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response. Cancer Res. 2006;66: Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34: Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bartsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011; 396: Gibril F, Venzon DJ, Ojeaburu JV, Bashir S, Jensen RT. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86: Machens A, Schaaf L, Karges W, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf). 2007;67: Lips CJ, Dreijerink KM, Hoppener JW. Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation. Clinics. 2012;67: Brandi ML, Gagl RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86: Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97: Thevenon J, Bourredjem A, Cardot-Bauters C, et al. Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d Etude des Tumeurs Endocrines (GTE) cohort study. Hum Mol Genet. 2013;22: Waldmann J, Fendrich V, Habbe N, et al. Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg. 2009;33: Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2010: Teh BT. Thymic carcinoids in multiple endocrine neoplasia type 1. J Intern Med. 1998;243: Goudet P, Bonithon-Kopp C, Murat A, et al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d Etude des Tumeurs Endocrines. Eur J Endocrinol. 2011;165: Weisbrod AB, Nilubol N, Weinstein LS, et al. Association of type 0 blood with neuroendocrine tumors in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2013;98:E109 E111.
Management of pancreatic neuroendocrine tumors in patients with MEN 1
Review Article Management of pancreatic neuroendocrine tumors in patients with MEN 1 Samira M. Sadowski 1, Frederic Triponez 2 1 Endocrine Oncology Branch, National Institutes of Health, Bethesda, MD 20892,
More informationDiagnosing and monitoring NET
Diagnosing and monitoring NET Inaccurate or delayed diagnosis of neuroendocrine tumors (NET) is common, because many NET are small and asymptomatic. 1 When symptoms are present, they are usually nonspecific
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationSurgical treatment and prognosis of gastrinoma
Best Practice & Research Clinical Gastroenterology Vol. 19, No. 5, pp. 799 805, 2005 doi:10.1016/j.bpg.2005.05.003 available online at http://www.sciencedirect.com 10 Surgical treatment and prognosis of
More informationManagement of Pancreatic Islet Cell Tumors
Management of Pancreatic Islet Cell Tumors Ravi Dhanisetty, MD November 5, 2009 Morbidity and Mortality Conference Case Presentation 42 yr female with chronic abdominal pain. PMHx: Uterine fibroids Medications:
More informationGrowth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study
Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study Authors Wouter F. W. Kappelle 1,GerlofD.Valk 2,MaxLeenders
More informationColor Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging
Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:
More informationEUS FNA NEUROENDOCRINE TUMORS. A. Ginès Endocopy Unit Hospital Cínic. Barcelona (Spain)
EUS FNA NEUROENDOCRINE TUMORS A. Ginès Endocopy Unit Hospital Cínic. Barcelona (Spain) GI NEUROENDOCRINE TUMORS GENERAL CONCEPTS Rare neoplasms arising from the neuroendocrine cells of the GI tract Include:
More informationIndex. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 15 (2006) 681 685 Index Note: Page numbers of article titles are in boldface type. A Ablative therapy, for liver metastases in patients with neuroendocrine tumors, 517 with radioiodine
More informationEndocrine Surgery. Characteristics of the Germline MEN1 Mutations in Korea: A Literature Review ORIGINAL ARTICLE. The Korean Journal of INTRODUCTION
ORIGINAL ARTICLE ISSN 1598-1703 (Print) ISSN 2287-6782 (Online) Korean J Endocrine Surg 2014;14:7-11 The Korean Journal of Endocrine Surgery Characteristics of the Germline MEN1 Mutations in Korea: A Literature
More informationMultiple endocrine neoplasia type 1 (MEN1) is an autosomal
ORIGINAL ARTICLES Outcome of Duodenopancreatic Resections in Patients With Multiple Endocrine Neoplasia Type 1 Detlef K. Bartsch, MD,* Volker Fendrich, MD,* Peter Langer, MD,* Ilhan Celik, MD, Peter H.
More informationDiagnostic Challenges in Multiple Endocrine Neoplasia Type 1 (MEN1) : Usefulness of Genetic Analysis
Diagnostic Challenges in Multiple Endocrine Neoplasia Type 1 (MEN1) : Usefulness of Genetic Analysis Professor R. V. Thakker, FRS May Professor of Medicine University of Oxford, U.K. Meet The Experts 49
More informationNeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction
NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Diagnostic & therapeutic
More informationDiagnosis abnormal morphology and /or abnormal biochemistry
Diagnosis abnormal morphology and /or abnormal biochemistry MEN 1 GEP Tumours Pancreatico-Nodal (-Duodenal) Affects 35-80% of MEN1 patients Functioning or non functioning Hyperplasia microadenoma macrotumours
More informationMultiple Endocrine Neoplasia Type 1
Journal of Surgical Oncology 2005;89:143 150 Multiple Endocrine Neoplasia Type 1 GERARD M. DOHERTY, MD* NW Thompson Professor of Surgery, University of Michigan, Ann Arbor, Michigan Multiple endocrine
More informationMULTIPLE endocrine neoplasia
PAPER Genotype-Phenotype Analysis in Multiple Endocrine Neoplasia Type 1 Maria A. Kouvaraki, MD, PhD; Jeffrey E. Lee, MD; Suzanne E. Shapiro, MS; Robert F. Gagel, MD; Steven I. Sherman, MD; Rena V. Sellin,
More informationResult Navigator. Positive Test Result: MEN1. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: MEN1 Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationGastrinoma: Medical Management. Haley Gallup
Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical
More informationNeuroendocrine Tumors
Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.
More informationType 2 gastric neuroendocrine tumor: report of one case
Case Report Type 2 gastric neuroendocrine tumor: report of one case Yuanliang Li, Xin Su, Huangying Tan Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China Correspondence
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationObjectives. Terminology 03/11/2013. Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors. Pathology Update 2013
Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors Pathology Update 2013 Ozgur Mete, MD Consultant in Endocrine Pathology, Department of Pathology, University Health Network Assistant
More informationOberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)
GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different
More informationGreater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Contents 14. Neuroendocrine Tumours 161 14.1. Diagnostic algorithm
More informationCONTINUING MEDICAL EDUCATION
CONTINUING MEDICAL EDUCATION :635-9 Carcinoma of Two Parathyroid Glands Caused by a Novel MEN1 Gene Mutation a Rare Feature of the MEN 1 Syndrome Linas Juodelė 1, Danielius Serapinas 2, Gintaras Sabaliauskas
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationConcurrent Type 2 Diabetes and Multiple Endocrine Neoplasia Type 1 With a Novel MEN1 Gene Mutation
Elmer ress Case Report J Med Cases. 2014;5(11):596-600 Concurrent Type 2 Diabetes and Multiple Endocrine Neoplasia Type 1 With a Novel MEN1 Gene Mutation Joung Wook Yang a, Su Kyoung Kwon a, c, Jeong Hoon
More informationPALB2 mutations in European familial pancreatic cancer families
Clin Genet 2010: 78: 490 494 Printed in Singapore. All rights reserved Short Report 2010 John Wiley & Sons A/S CLINICAL GENETICS doi: 10.1111/j.1399-0004.2010.01425.x PALB2 mutations in European familial
More informationAn Unexpected Cause of Hypoglycemia
An Unexpected Cause of Hypoglycemia Stacey A. Milan, MD FACS Surgical Oncology Nothing to disclose Disclosures Objectives Identify indications for workup of hypoglycemia Define work up for hypoglycemic
More informationImaging and Management of Pancreatic Endocrine Tumors in MEN 1
October 20, 2008 Imaging and Management of Pancreatic Endocrine Tumors in MEN 1 Marie Elaine Stevens Georgetown University School of Medicine, Year IV Dr. Agenda Discuss Our Patient s Presentation Review
More informationAN ARGUMENT FOR SURGERY FOR GASTRINOMA. Lauren Wilson R1 General Surgery
AN ARGUMENT FOR SURGERY FOR GASTRINOMA Lauren Wilson R1 General Surgery WHAT IS A GASTRINOMA? Gastrin secreting cells derived from multipotential stem cells of endodermal origin or enteroendocrine cells
More informationLu Hao Feng et al., IJSIT, 2016, 5(6),
AN UNUSUAL PRESENTATION OF PANCREATIC VASOACTIVE INTESTINAL PEPTIDE TUMOUR (VIP OMAS) WITH GASTROINTESTINAL STROMAL TUMOUR (GIST) WITHOUT HYPOKALEMIA AND HPERCALCEMIA: A CASE REPORT WITH REVIEW ARTICLES
More information3/22/2017. Disclosure of Relevant Financial Relationships. Ki-67 in Pancreatic Neuroendocrine Neoplasms According to WHO 2017.
Disclosure of Relevant Financial Relationships Ki-67 in Pancreatic Neuroendocrine Neoplasms According to WHO 2017. USCAP requires that all planners (Education Committee) in a position to influence or control
More informationImaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear
Imaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear Eric Tamm, M.D. Department of Diagnostic Radiology Division of Diagnostic Imaging MD Anderson Cancer Center Houston, TX Disclosure
More informationSurgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1
CLINICS 2012;67(S1):173-178 DOI:10.6061/clinics/2012(Sup01)29 REVIEW Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1 Göran Åkerström, Peter Stålberg,
More informationRadiology Pathology Conference
Radiology Pathology Conference Nadia F. Yusaf, M.D. PGY-3 1/29/2010 Presentation material is for education purposes only. All rights reserved. 2010 URMC Radiology Page 1 of 90 Case 1 60 year- old man presents
More informationEndocrine pancreatic tumors: factors correlated with survival
Original article Annals of Oncology 6: 86 8, 25 doi:.93/annonc/mdi358 Published online 5 August 25 Endocrine pancreatic tumors: factors correlated with survival P. Tomassetti *, D. Campana, L. Piscitelli,
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.
More informationMultiple endocrine neoplasia type 1: duodenopancreatic tumours
Journal of Internal Medicine 2003; 253: 590 598 MINISYMPOSIUM Multiple endocrine neoplasia type 1: duodenopancreatic tumours G. M. DOHERTY & N. W. THOMPSON Division of Endocrine Surgery, Department of
More informationSurgical treatment of neuroendocrine metastases
Best Practice & Research Clinical Gastroenterology Vol. 19, No. 4, pp. 577 583, 2005 doi:10.1016/j.bpg.2005.04.003 available online at http://www.sciencedirect.com 6 Surgical treatment of neuroendocrine
More informationCarcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011
Carcinoid Tumors: The Beginning and End Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 1 st described by Oberndofer(1907) Karzinoide = cancer like Arise from
More information1. Multiple Endocrine Neoplasia Type 1
1. Multiple Endocrine Neoplasia Type 1 Rajesh V. Thakker, MD, FRCP, FRCPath, FMedSci Clinical Features and Diagnosis Multiple endocrine neoplasia type 1 (MEN1), which is inherited as an autosomal dominant
More informationLong-Term Effect of External Beam Radiotherapy of Optic Disc Hemangioma in a Patient with von Hippel-Lindau Disease
2011 65 2 135 141 Long-Term Effect of External Beam Radiotherapy of Optic Disc Hemangioma in a Patient with von Hippel-Lindau Disease a* b c c d e f g a b c f g d e 136 65 2 ʼ ʼ ʼ April 2011 Radiation
More informationInsulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens
Insulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens Kartik Viswanathan, M.D., Ph.D New York Presbyterian - Weill
More informationGEP NEN. Personalised approach. Curative and Palliative Surgery. ESMO Preceptorship Programme Neuroendocrine Neoplasms Lugano April 2018
GEP NEN Personalised approach Curative and Palliative Surgery ESMO Preceptorship Programme Neuroendocrine Neoplasms Lugano 13 14 April 2018 Professor Andrea Frilling Department of Surgery and Cancer Imperial
More informationFactors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience
RESEARCH ARTICLE Editorial Process: Submission:00/00/0000 Acceptance:00/00/0000 : A 15-Year Single Center Experience Abdullah Sakin 1 *, Makbule Tambas 2, Saban Secmeler 3, Orçun Can 3, Serdar Arici 3,
More informationPancreatic polypeptide secreting tumors an institutional experience and review of the literature
ORIGINAL ARTICLE Pancreatic polypeptide secreting tumors an institutional experience and review of the literature Angela Tatiana Alistar 1, Michelle Kang Kim 2, Richard Warner 2, Erin Moshier 3, Randall
More informationMutation analysis in two Chinese families with multiple endocrine neoplasia type 1
original article Mutation analysis in two Chinese families with multiple endocrine neoplasia type 1 Análise de mutações em duas famílias chinesas com neoplasia endócrina múltipla tipo 1 Zhang Wen 1, Quan
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationNeuroendocrine Tumor of Unknown Primary Accompanied with Stomach Adenocarcinoma
J Gastric Cancer 2011;11(4):234-238 http://dx.doi.org/10.5230/jgc.2011.11.4.234 Case Report Neuroendocrine Tumor of Unknown Primary Accompanied with Stomach Adenocarcinoma Ho-Yeun Kim, Sung-Il Choi 1,
More informationB. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.
B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life. b. Deficiency of dietary iodine: - Is linked with a
More informationDavid Bruyette, DVM, DACVIM Medical Director
VCAWLAspecialty.com David Bruyette, DVM, DACVIM Medical Director The pancreas is made up of endocrine and exocrine tissue. The endocrine pancreas is composed of islets of Langerhans, which make up approximately
More informationLong-term outcome of Multiple Endocrine Neoplasia type 1 related manifestations
Long-term outcome of Multiple Endocrine Neoplasia type 1 related manifestations Results from the DutchMEN1 Study Group Carolina R.C. Pieterman Long-term outcome of Multiple Endocrine Neoplasia Type 1 related
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationSandostatin LAR for functional neuroendocrine tumor in MEN 1
ase Report 1 Sandostatin LR for functional neuroendocrine tumor in MEN 1 uthors: ho-lun Tsai, 1 M.., Tsu-Yao heng, 2,3 M.., Hsiu-Po Wang, 3 M.. ffiliation: 1. epartment of Internal Medicine, itmanson Medical
More informationTumor markers. Chromogranin A. Analyte Information
Tumor markers Chromogranin A Analyte Information -1-2018-04-22 Chromogranin A Introduction Chromogranin A (CgA) is a 439-amino acid protein with a molecular weight of 48 to 60 kda, depending on glycosylation
More informationCase Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors
Case Presentation Marianne Ellen Pavel Charité University Medicine Berlin ESMO Preceptorship on GI Neuroendocrine Tumors Session 3; Singapore November 2, 2012 06.11.2012 Medical History 46-year-old man
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationPrinciples of diagnosis, work-up and therapy The Gastroenterologist s role
Principles of diagnosis, work-up and therapy The Gastroenterologist s role Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University
More informationACTH Producing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
CASE REPORT ACTH Producing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Aura D Herrera-Martinez, José Carlos Padillo Cuenca, Rodrigo Bahamondes Opazo, Ana Barrera Martín, Angel
More informationNeuro-endocrine and pancreatic non-adenocarcinomas. Marc Engelbrecht, AMC, Amsterdam
Neuro-endocrine and pancreatic non-adenocarcinomas Marc Engelbrecht, AMC, Amsterdam Pancreatic Tumors q Epithelial Exocrine q Mesenchymal Ductal Adenocarcinoma (85-95%) Metastasis Lymfoma Acinar Cell Carcinoma
More informationNEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS. BY: Shifaa Qa qa
NEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS BY: Shifaa Qa qa Neoplasmas of the thyroid thyroid nodules Neoplastic ---- benign, malignant Non neoplastic Solitary nodules ----- neoplastic Nodules
More informationA retrospective analysis of neuroendocrine tumour of pancreas: a single institute study
International Journal of Research in Medical Sciences Chheda YP et al. Int J Res Med Sci. 2015 Nov;3(11):3041-3045 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20150928
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationIndex. radiologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC. See Adrenal cortical carcinoma. Acromegaly and the pituitary gland, 551 Acute suppurative thyroiditis, 405, 406 Addison, Thomas and
More information5/1/2010. Genetic testing in patients with endocrine tumors. Genetic testing in Patients with Endocrine Tumors
Genetic testing in patients with endocrine tumors Why? Jessica E. Gosnell MD Assistant Prof of Surgery April 30, 2010 Genetic testing in Patients with Tumors Indications & Interpretation Germline mutations
More informationSurgical Therapy of GEP-NET: An Overview
Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior
More informationCalcitonin. 1
Calcitonin Medullary thyroid carcinoma (MTC) is characterized by a high concentration of serum calcitonin. Routine measurement of serum calcitonin concentration has been advocated for detection of MTC
More informationPancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case
Case Report Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Yang Wang, Dongbing Zhao Department of Abdominal Surgery, Cancer Institute & Hospital,
More informationEndocrine Tumors of the Gastrointestinal System. F. V. Nowak Ohio University March 22, 2005
Endocrine Tumors of the Gastrointestinal System F. V. Nowak Ohio University March 22, 2005 Gastroenteropancreatic Endocrine System Clear cells of endodermal origin found in the pancreas, stomach, small
More informationFast, automated, precise
Thermo Scientific B R A H M S / NSE Immunodiagnostic Assays Fast, automated, precise Neuroendocrine tumor markers on KRYPTOR Systems First and only fully automated CgA assay worldwide Shortest time to
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationCRITICAL ANALYSIS OF NEN GUIDELINES. G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines
CRITICAL ANALYSIS OF NEN GUIDELINES G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines DISCLOSURES NO CONFLICTS OF INTEREST TO DECLARE UPDATED
More informationCASE REPORT. Introduction. Case Report. Kimitoshi Kubo 1, Noriko Kimura 2, Katsuhiro Mabe 1, Yusuke Nishimura 1 and Mototsugu Kato 1
doi: 10.2169/internalmedicine.0842-18 Intern Med 57: 2951-2955, 2018 http://internmed.jp CASE REPORT Synchronous Triple Gastric Cancer Incorporating Mixed Adenocarcinoma and Neuroendocrine Tumor Completely
More informationTriage of Limited Versus Extensive Disease on 18 F-FDG PET/CT Scan in Small Cell lung Cancer
Triage of Limited Versus Extensive Disease on F-FDG PET/CT Scan in Small Cell lung Cancer Riaz Saima 1*, Bashir Humayun 1, Niazi Imran Khalid 2 1 Department of Nuclear Medicine, Shaukat Khanum Memorial
More informationIdentification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome
Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome L.H. Cao 1, B.H. Kuang 2, C. Chen 1, C. Hu 2, Z. Sun 1, H. Chen 2, S.S. Wang
More informationMultiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings
CASE REPORT Ochsner Journal 18:170 175, 2018 Academic Division of Ochsner Clinic Foundation DOI: 10.31486/toj.17.0019 Multiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings
More informationDiagnosis and Management of Multiple Endocrine Neoplasia Type 1 (MEN1)
Hereditary Cancer in Clinical Practice 2005; 3(1) pp. 1-6 Diagnosis and Management of Multiple Endocrine Neoplasia Type 1 (MEN1) Koen M.A. Dreijerink, Cees J.M. Lips Department of Endocrinology, University
More informationA variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study
ORIGINAL ARTICLE A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study Joon-Hyop Lee, MD, Yoo Seung Chung, MD, PhD,* Young Don Lee, MD, PhD
More informationCase Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT
Case Report 8-YEAR SURVIVAL WITH A METASTATIC THYMIC NEUROENDOCRINE TUMOR: EMPHASIS ON REDEFINING TREATMENT OBJECTIVES USING PERSONALIZED PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177 Lu- AND 90 Y-LABELED
More informationIntertumor heterogeneity in 60 pancreatic neuroendocrine tumors associated with multiple endocrine neoplasia type 1
Selberherr et al. Orphanet Journal of Rare Diseases (2019) 14:54 https://doi.org/10.1186/s13023-019-1034-4 RESEARCH Open Access Intertumor heterogeneity in 60 pancreatic neuroendocrine tumors associated
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationA Case of Pancreatic Neuroendocrine Tumor presenting Iron Deficiency Anemia in a Patient with Neurofibromatosis Type 1
A Case of Pancreatic Neuroendocrine Tumor presenting Iron Deficiency Anemia in a Patient with Neurofibromatosis Xueyu Sun 1, Yanan Yu 1, Yueping Jiang 1, Deming Li 1 1 Department of Gastroenterology, The
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationACTH-producing neuroendocrine tumor of the pancreas: a case report and literature review
Ann Hepatobiliary Pancreat Surg 2017;21:61-65 https://doi.org/10.14701/ahbps.2017.21.1.61 Case Report ACTH-producing neuroendocrine tumor of the pancreas: a case report and literature review Justin Byun
More informationA KINDRED WITH a RET CODON Y791F MUTATION PRESENTING WITH HIRSCHSPRUNG S S DISEASE.
A KINDRED WITH a RET CODON Y791F MUTATION PRESENTING WITH HIRSCHSPRUNG S S DISEASE. ד"ר מרב פרנ קל ד גנית ברק גרוס דיויד פרופסור השרות לאנדוקרינ ולוגיה ומטבוליזם ירושלים ה דסה עין כר םם, Case Report 36
More informationDisorders of Cell Growth & Neoplasia
General Pathology VPM 152 Disorders of Cell Growth & Neoplasia Lecture 3 Rate of growth, local invasion, and metastasis. Molecular basis of cancer (normal cell-cycle and cellular proliferation). Enrique
More informationObjective: To improve the knowledge of MEN1 natural history before 21 years old.
ORIGINAL ARTICLE MEN1 Disease Occurring Before 21 Years Old: A 160-Patient Cohort Study From the Groupe d étude des Tumeurs Endocrines P. Goudet, A. Dalac, M. Le Bras, C. Cardot-Bauters, P. Niccoli, N.
More informationUniversity of Groningen
University of Groningen Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group Pieterman, Carolina R. C.; de Laat, Joanne M.; Twisk,
More informationSCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions
MONDAY TEACHING SCOPE TODAYS SESSION Case 1: Basic Questions Case 2 Basic Questions Basic Theory Stuff: AJCC TNM + Stage Group for Carcinoid of the Appendix Management of Carcinoid of the Appendix (NCCN)
More informationSuperior mediastinal paraganglioma associated with von Hippel-Lindau syndrome: report of a case
Takahashi et al. World Journal of Surgical Oncology 2014, 12:74 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Superior mediastinal paraganglioma associated with von Hippel-Lindau syndrome:
More informationSurveillance in patients with chronic pancreatitis or hereditary risks
European Digestive Cancer Days 2017 26 th September Prague Surveillance in patients with chronic pancreatitis or hereditary risks J. Rosendahl Universitätsklinik für Innere Medizin I Universitätsklinikum
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Update of mixed tumours of the GI tract, the pancreas and the liver Introduction to the concept of mixed tumours and clinical implication Jean-Yves SCOAZEC Surgical
More informationLE FORME FAMILIARI. quando pensare alla MEN1?
dal 1846 AGGIORNAMENTI NELL APPROCCIO DIAGNOSTICO-TERAPEUTICO AI TUMORI NEUROENDOCRINI GASTRO-ENTERO-PANCREATICI LE FORME FAMILIARI GEP-NET: quando pensare alla MEN1? Mariella Minoia Maria Chiara Zatelli
More informationClinical Case Seminar A4( 1-5)
Clinical Case Seminar A4( 1-5) An extremely rare association of TSH-secreting pituitary adenoma, metastatic neuroendocrine tumor and Cushing s syndrome in a patient with MEN-1 gene mutation Giuseppe Giuffrida
More informationcolorectal cancer Colorectal cancer hereditary sporadic Familial 1/12/2018
colorectal cancer Adenocarcinoma of the colon and rectum is the third most common site of new cancer cases and deaths in men (following prostate and lung or bronchus cancer) and women (following breast
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More information